Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs

Vor Biopharma

11/08/2026 14:42

Overview
US biotech firm's Q2 net loss widened, missing analyst expectations
R&D expenses dropped sharply yr/yr due to prior licensing costs and workforce reductions
Company projects cash runway into early 2029

Outlook
Vor Bio anticipates topline Phase 3 UPSTREAM MG trial results in 1H 2027
Company expects cash and investments to fund operations into early 2029
Enrollment ongoing for Phase 3 UPSTREAM SjD trial in primary Sjögren’s disease

Result Drivers
R&D EXPENSE DROP - Co said Q2 R&D expenses fell mainly due to prior licensing costs and workforce reductions in Q2 2025, partially offset by increased spending on new programs
G&A EXPENSE INCREASE - Co attributed higher Q2 G&A expenses to increased stock-based compensation, personnel, and commercial-related costs
WARRANT FAIR VALUE CHANGE - Co said net loss narrowed mainly due to change in fair value of liability-classified warrants compared to prior yr

Company press release: ID:nGNX7zzzNx

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$62.80 mln
$35.68 mln (9 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vor Biopharma Inc. is $40.00, about 71.2% above its August 10 closing price of $23.37

Reuters Recommended Reads
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 11 - UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Aug 11 - Achieve Life Sciences Q2 loss widens on warrant liabilities

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)